Method of treating androgenic alopecia with 5.alpha.-reductase i

Details Method of treating androgenic alopecia with 5.alpha.-reductase i Method of treating androgenic alopecia with 5.alpha.-reductase i

1998-06-22

1999-11-09

Rose, Shep K.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

A61K 3144, A61K 3158

Patent

active

059815434

ABSTRACT:
The instant invention involves a method of treating and/or reversing androgenic alopecia and promoting hair growth, and methods of treating acne vulgaris, seborrhea, and female hirsutism, by administering to a patient in need of such treatment a 5.alpha.-reductase 2 inhibitor such as finasteride, in a dosage amount under 5 mgs/day.

REFERENCES:
patent: 4377584 (1983-03-01), Rasmusson et al.
patent: 4396615 (1983-08-01), Petrow et al.
patent: 4684635 (1987-08-01), Orentreich et al.
patent: 4760071 (1988-07-01), Rasmusson et al.
patent: 4885289 (1989-12-01), Breuer et al.
patent: 5053403 (1991-10-01), Orentreich et al.
patent: 5175155 (1992-12-01), Juniewicz et al.
patent: 5228431 (1993-07-01), Giaretto
patent: 5407944 (1995-04-01), Goldman
patent: 5438061 (1995-08-01), Bergman et al.
patent: 5480889 (1996-01-01), Goldman
patent: 5512555 (1996-04-01), Waldstreicher
patent: 5525608 (1996-06-01), Adams et al.
patent: 5567708 (1996-10-01), Rasmusson et al.
patent: 5571817 (1996-11-01), Rasmusson et al.
patent: 5595996 (1997-01-01), Graham et al.
patent: 5610162 (1997-03-01), Witzel et al.
patent: 5708001 (1998-01-01), Andrews et al.
patent: 5730964 (1998-03-01), Waldstreicher et al.
patent: 5756507 (1998-05-01), Goulet et al.
patent: 5777134 (1998-07-01), Bakshi et al.
patent: 5780437 (1998-07-01), Goulet et al.
patent: 5795882 (1998-08-01), Bishop et al.
patent: 5843953 (1998-12-01), Graham et al.
patent: 5846976 (1998-12-01), Batchelor et al.
patent: 5849764 (1998-12-01), Goulet et al.
Gormley et al., J. Clin. Endo. Metab., vol. 70, pp. 1136-1141 (1990), "Effects of finasteride (MK-906), a 5alpha-reductase inhibitor, on circulating androgens in male volunteers" Transcript, WNBC-TV, News 4 NY Live at Five, Nov. 29, 1993.
Diani et al., J. Clin. Endo. Metab., vol. 74, pp. 345-350 (1992), "Hair growth effects on oral admin. of finasteride, a steroid 5alpha-reductase inhibitor . . . ".
Imperato-McGinley et al., J. Clin. Endoc. Metab., vol. 70, pp. 777-782 (1990), "The 5-alpha reductase inhibitor finasteride comparison of male pseudohermaphrodites . . . ".
Bingham et al., J. Endoc., vol. 57, pp. 111-121 (1973), "The metabolism of testosterone by human male scalp skin".
Stoner et al., Prostate, vol. 22, pp. 291-299 (1993), "Finasteride (MK-906) in the treatment of benign prostatic hyperplasia".
Stoner et al., J. Urol., vol. 147, pp. 1298-1302 (1992), "The clinical effects of a 5-alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia".
Sudduth et al., Pharmacotheraphy, vol. 13, pp. 309-325 (Jul.-Aug. 1993), "Finasteride: The first 5-alpha-reductase inhibitor".
Gormley et al., New England J. Med., vol. 327, pp. 1185-1191 (1992), "The effect of finasteride in men with benign prostatic hyperplasia".
Matzkin et al., Clin. Endocrinol., vol. 37, pp. 432-436 (1992), "Prolonged treatment with finasteride (a 5-alpha-reductase inhibitor) dose not affect bone density and metabolism".
McConnell et al., J. Urol., vol. 143, No. 4, Suppl., p. 267A (1990), "The effects of low-dose finsteride (MK-906) on prostatic androgen levels in men with benign prostatic . . . ".
McConnell et al., J. Clin. Endoc. Metab., vol. 74, pp. 505-508 (Mar. 1992), "Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men . . . ".
Vermeulen et al., Eur. Urol., vol. 20, Supp. 1, pp. 82-86 (1991), "Hormonal effects of 5alpha reductase inhibitor (Finasteride) . . . ".
Vermeulen et al., Prostate, vol. 14, pp. 45-53 (1989), "Hormonal effects of an orally active 4-azasteroid inhibitor of 5-alpha-reductase in humans".
Metacalf et al., Trends Pharmacol. Sci., vol. 10, pp. 491-495 (1989), "Inhibitors of steroid 5-alpha-reductase in benign prostatic hyperplasia, male pattern baldness and acne".
Tempany et al., Prostate, vol. 22, pp. 39-42 (1993), "The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate . . . ".
Diani et al., Chem. Abstracts, vol. 116, Abstract No. 241714e.
Gormley et al., Prob. in Urology, vol. 5, No. 3, pp. 436-440 (1991), "The role of 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia".
Rittmaster et al., J. Clin. Endoc. Metab., vol. 65, No. 1, pp. 188-193 (1987), "The effects of N,N-diethyl-4-methyl-3-oxo-4-aza-5alpha-androstane-17beta-carboxamide, a 5alpha-reductase inhibitor and antiandrogen, on the development of baldness . . . ".
Mellin et al., J. Steroid Biochem. Mol. Biol., vol. 44, No. 2, pp. 121-131 (1993), "Azasteroids as inhibitors of testosterone 5alpha-reductase in mammalian skin".
Stoner, J. Steroid Biochem. Mol. Biol., vol. 37, No. 3, pp. 375-378 (1990), "The clinical development of a 5alpha-reductase inhibitor, finasteride".
Dallob, J. Clin. Endoc. Metab., vol. 79, No. 3, pp. 703-706 (1994), "The effect of finasteride, a 5alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations . . . ".
Waldstreicher et al., J. Invest. Derma. 102(4) 1994, p. 615, Item No. 549, "Effects of finasteride on dihydrotestosterone content of scalp skin in men with male pattern baldness".
Shupack et al., Int. J. Dermat. 31(10)1993, pp. 701-706, "Status of medical treatment for androgenetic alopecia".
Kaufman et al., J. Invest. Derma. 102(4) 1994, p. 615, Item No. 550, "Effects of finasteride on dihydrotestosterone content of scalp skin in men with male pattern baldness".
Rhodes et al., J. Clin. Endocrin. & Metab. 79(4), 1994, pp. 991-996, "The effects of finasteride (Proscar) on hair growth, hair cycle stage, and serum testosterone and dihydrotestosterone in adult male and female stumptail macaques (Macaca arctoides)".
Steiner, Clin. Pharm. (USA) 12(1) 1993, pp. 15-23, "Finasteride: A 5alpha-reductase inhibitor".
Gormley, Drug Research Reports: The Blue Sheet, vol. 35, No. 20, 1992, pp. 6-7, "Proscar in clincals for chemoprevention following prosatectomy".
Sawaya et al., Dermatol. Clin. (USA) 11(1) 1993, pp. 65-72, "The antiandrogens: when and how they should be used".
Simpson, J. Derm. Treat., (1989), pp. 107-109, "The management of androgenic alopecia in women".
Muller et al., Small Animal Dermat. 2nd ed. (1976), pp. 491-501, "Alopecias".

Affiliated with

Also associated with

Rating

Method of treating androgenic alopecia with 5.alpha.-reductase i does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of treating androgenic alopecia with 5.alpha.-reductase i, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating androgenic alopecia with 5.alpha.-reductase i will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1456402